Literature DB >> 32139509

RPTPα phosphatase activity is allosterically regulated by the membrane-distal catalytic domain.

Yutao Wen1,2, Shen Yang1, Kuninobu Wakabayashi1,3, Mattias N D Svensson1, Stephanie M Stanford1,3, Eugenio Santelli1,3, Nunzio Bottini4,3.   

Abstract

Receptor-type protein tyrosine phosphatase α (RPTPα) is an important positive regulator of SRC kinase activation and a known promoter of cancer growth, fibrosis, and arthritis. The domain structure of RPTPs comprises an extracellular region, a transmembrane helix, and two tandem intracellular catalytic domains referred to as D1 and D2. The D2 domain of RPTPs is believed to mostly play a regulatory function; however, no regulatory model has been established for RPTPα-D2 or other RPTP-D2 domains. Here, we solved the 1.8 Å resolution crystal structure of the cytoplasmic region of RPTPα, encompassing D1 and D2, trapped in a conformation that revealed a possible mechanism through which D2 can allosterically inhibit D1 activity. Using a D2-truncation RPTPα variant and mutational analysis of the D1/D2 interfaces, we show that D2 inhibits RPTPα phosphatase activity and identified a 405PFTP408 motif in D1 that mediates the inhibitory effect of D2. Expression of the gain-of-function F406A/T407A RPTPα variant in HEK293T cells enhanced SRC activation, supporting the relevance of our proposed D2-mediated regulation mechanism in cell signaling. There is emerging interest in the development of allosteric inhibitors of RPTPs but a scarcity of validated allosteric sites for RPTPs. The results of our study not only shed light on the regulatory role of RPTP-D2 domains, but also provide a potentially useful tool for the discovery of chemical probes targeting RPTPα and other RPTPs.
© 2020 Wen et al.

Entities:  

Keywords:  allosteric regulation; cancer; cell signaling; crystal structure; protein phosphatase; protein structure; signal transduction; tyrosine-protein phosphatase (tyrosine phosphatase)

Mesh:

Substances:

Year:  2020        PMID: 32139509      PMCID: PMC7152759          DOI: 10.1074/jbc.RA119.011808

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  Dimerization in vivo and inhibition of the nonreceptor form of protein tyrosine phosphatase epsilon.

Authors:  Hila Toledano-Katchalski; Zohar Tiran; Tal Sines; Gidi Shani; Shira Granot-Attas; Jeroen den Hertog; Ari Elson
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

2.  Kinetic analysis of two closely related receptor-like protein-tyrosine-phosphatases, PTP alpha and PTP epsilon.

Authors:  K L Lim; D S Lai; M B Kalousek; Y Wang; C J Pallen
Journal:  Eur J Biochem       Date:  1997-05-01

3.  Drugging the Undruggable: Therapeutic Potential of Targeting Protein Tyrosine Phosphatases.

Authors:  Zhong-Yin Zhang
Journal:  Acc Chem Res       Date:  2016-12-15       Impact factor: 22.384

4.  Allosteric inhibition of protein tyrosine phosphatase 1B.

Authors:  Christian Wiesmann; Kenneth J Barr; Jenny Kung; Jiang Zhu; Daniel A Erlanson; Wang Shen; Bruce J Fahr; Min Zhong; Lisa Taylor; Mike Randal; Robert S McDowell; Stig K Hansen
Journal:  Nat Struct Mol Biol       Date:  2004-07-18       Impact factor: 15.369

5.  The second domain of the CD45 protein tyrosine phosphatase is critical for interleukin-2 secretion and substrate recruitment of TCR-zeta in vivo.

Authors:  N Kashio; W Matsumoto; S Parker; D M Rothstein
Journal:  J Biol Chem       Date:  1998-12-11       Impact factor: 5.157

6.  Receptor Protein Tyrosine Phosphatase α-Mediated Enhancement of Rheumatoid Synovial Fibroblast Signaling and Promotion of Arthritis in Mice.

Authors:  Stephanie M Stanford; Mattias N D Svensson; Cristiano Sacchetti; Caila A Pilo; Dennis J Wu; William B Kiosses; Annelie Hellvard; Brith Bergum; German R Aleman Muench; Christian Elly; Yun-Cai Liu; Jeroen den Hertog; Ari Elson; Jan Sap; Piotr Mydel; David L Boyle; Maripat Corr; Gary S Firestein; Nunzio Bottini
Journal:  Arthritis Rheumatol       Date:  2016-02       Impact factor: 10.995

Review 7.  Protein tyrosine phosphatases in the human genome.

Authors:  Andres Alonso; Joanna Sasin; Nunzio Bottini; Ilan Friedberg; Iddo Friedberg; Andrei Osterman; Adam Godzik; Tony Hunter; Jack Dixon; Tomas Mustelin
Journal:  Cell       Date:  2004-06-11       Impact factor: 41.582

8.  Protein tyrosine phosphatase alpha (PTPalpha) and contactin form a novel neuronal receptor complex linked to the intracellular tyrosine kinase fyn.

Authors:  L Zeng; L D'Alessandri; M B Kalousek; L Vaughan; C J Pallen
Journal:  J Cell Biol       Date:  1999-11-15       Impact factor: 10.539

9.  PTPσ inhibitors promote hematopoietic stem cell regeneration.

Authors:  Yurun Zhang; Martina Roos; Heather Himburg; Christina M Termini; Mamle Quarmyne; Michelle Li; Liman Zhao; Jenny Kan; Tiancheng Fang; Xiao Yan; Katherine Pohl; Emelyne Diers; Hyo Jin Gim; Robert Damoiseaux; Julian Whitelegge; William McBride; Michael E Jung; John P Chute
Journal:  Nat Commun       Date:  2019-08-14       Impact factor: 14.919

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  4 in total

1.  Ethyl Gallate Dual-Targeting PTPN6 and PPARγ Shows Anti-Diabetic and Anti-Obese Effects.

Authors:  Dohee Ahn; Jinsoo Kim; Gibeom Nam; Xiaodi Zhao; Jihee Kwon; Ji Young Hwang; Jae Kwan Kim; Sun-Young Yoon; Sang J Chung
Journal:  Int J Mol Sci       Date:  2022-04-30       Impact factor: 6.208

2.  The receptor PTPRU is a redox sensitive pseudophosphatase.

Authors:  Iain M Hay; Gareth W Fearnley; Pablo Rios; Maja Köhn; Hayley J Sharpe; Janet E Deane
Journal:  Nat Commun       Date:  2020-06-26       Impact factor: 14.919

3.  Structure-Activity Relationship of Synthetic Ginkgolic Acid Analogs for Treating Type 2 Diabetes by PTPN9 Inhibition.

Authors:  Jinsoo Kim; Jinyoung Son; Dohee Ahn; Gibeom Nam; Xiaodi Zhao; Hyuna Park; Woojoo Jeong; Sang J Chung
Journal:  Int J Mol Sci       Date:  2022-04-01       Impact factor: 5.923

4.  Does a rare mutation in PTPRA contribute to the development of Parkinson's disease in an Australian multi-incident family?

Authors:  Melissa A Hill; Steven R Bentley; Tara L Walker; George D Mellick; Stephen A Wood; Alex M Sykes
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.